Tuberculosis Program

About Fimbrion Therapeutics

Fimbrion Therapeutics is pioneering an antibiotic-sparing approach to combat bacterial infections through its antivirulence platform. The company has established a significant partnership with GSK, which has advanced a UTI candidate into Phase I clinical trials and secured CARB-X funding for its development. With strong academic roots, NIH SBIR grant support, and a focus on high-need areas like recurrent UTIs and tuberculosis, Fimbrion is positioned as an innovator in addressing the global antimicrobial resistance crisis.

About PAI Life Sciences

PAI Life Sciences is a private, clinical-stage biotech with a dual mission: serving as a key supplier of research adjuvants and developing a proprietary pipeline targeting neglected tropical diseases (NTDs). Its core strategy is 'Serving the Underserved,' addressing diseases overlooked by larger pharmaceutical companies. The company has advanced its lead schistosomiasis vaccine candidate into human clinical trials (Phase 1 initiated in May 2022) and maintains a broader pipeline including programs for lymphatic filariasis, tuberculosis, and onchocerciasis. While currently pre-revenue from its therapeutic pipeline, it generates early revenue through its adjuvant supply business.

Therapeutic Areas

Other Tuberculosis Drugs